Last reviewed · How we verify
NCT06069310: MepoRiNaPAs
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
trial testing Mepolizumab 100 MG in Chronic Rhinosinusitis With Nasal Polyps in 40 participants. Participants enrolled and being followed up; not accepting new ones.
31 August 2026
Quick facts
| Lead sponsor | National and Kapodistrian University of Athens |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 September 2023 |
| Primary completion | 31 August 2026 |
| Estimated completion | 30 March 2027 |
| Sites | 2 locations across Greece |
Drugs / interventions tested
- Mepolizumab 100 MG — full drug profile →
Conditions studied
- Chronic Rhinosinusitis With Nasal Polyps — all drugs for Chronic Rhinosinusitis With Nasal Polyps →
- Severe Eosinophilic Asthma — all drugs for Severe Eosinophilic Asthma →
- Chronic Rhinosinusitis Without Nasal Polyps — all drugs for Chronic Rhinosinusitis Without Nasal Polyps →
Sponsor
National and Kapodistrian University of Athens
Who can join
18 and older, any sex, with Chronic Rhinosinusitis With Nasal Polyps or Severe Eosinophilic Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about clinical and functional outcomes in patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma and patients with Chronic rhinosinusitis with nasal polyps only treated with mepolizumab compared to healthy controls. Participants will be asked to give nasal, blood and sputum samples before mepolizumab administration (T0) and at 3 (T3), 6 (T6) and 12 (T12) months after mepolizumab initiation The main aims are to identify airways microbiota modifications and differential gene expression after mepolizumab initiation. Researchers will compare: * Patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma * Patients with Chronic rhinosinusitis with nasal polyps only * Healthy subjects The research will address the following questions: 1. What are the prospective clinical and functional outcomes of mepolizumab treatment 2. What is the impact of mepolizumab therapy on the airways microbiota and how this may relate to a potentially reduced need for steroids 3. What are the host differential gene expression patterns and the immune/inflammatory (cytokines/chemokines) profile alterations in airways microenvironment and in systemic circulation in response to therapy 4. What are the associations between host and microbiome variables for building up diagnostic and predictive biomarker classifiers of responsive disease endotypes
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.
Alska E, Łaszczych D, Napiórkowska-Baran K, Szymczak B, et al · · 2025 · cited 13× · PMID 40004611 · DOI 10.3390/jcm14041079
Verify or expand the search:
- PubMed search for NCT06069310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mepolizumab 100 MG
Trials testing the same drug.
- NCT05365841 — Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis · unknown
- NCT04914078 — Severe Asthma Exacerbations and Mepolizumab Treatment · unknown
- NCT04641741 — Effect of Mepolizumab on Severe Eosinophilic Asthma · unknown
- NCT05441059 — Use of Nucala in Severe Asthma · completed
Other recruiting trials for Chronic Rhinosinusitis With Nasal Polyps
Currently open trials in the same condition.
- NCT07187583 — Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps · Phase 4 · recruiting
- NCT06914908 — Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Poly · Phase 2 · recruiting
- NCT06834347 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Ina · Phase 3 · recruiting
- NCT06834360 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Ina · Phase 3 · recruiting
- NCT06706817 — A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initia · Phase 3 · recruiting
Other National and Kapodistrian University of Athens trials
Trials by the same sponsor.
- NCT07295964 — Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial · NA · not yet recruiting
- NCT07351981 — TcPRF for Knee Osteoarthritis · NA · enrolling by invitation
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
- NCT07295899 — Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Impl · not yet recruiting
- NCT06903130 — Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sN · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06069310 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National and Kapodistrian University of Athens
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06069310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing